Fleury SA
BOVESPA:FLRY3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fleury SA
BOVESPA:FLRY3
|
BR |
|
Plant Health Care PLC
LSE:PHC
|
US |
|
JSL SA
BOVESPA:JSLG3
|
BR |
|
Vinati Organics Ltd
NSE:VINATIORGA
|
IN |
|
DraftKings Inc
NASDAQ:DKNG
|
US |
Fleury SA
Fleury SA, originally founded in 1926, stands as a paragon of healthcare excellence in Brazil, evolving over nearly a century into a leading provider of medical diagnostics and integrated healthcare services. Driven by a culture of innovation and customer commitment, the company operates a network of strategically located diagnostic centers, offering a comprehensive array of tests, from basic blood work to sophisticated imaging. At the core of Fleury's operations is their ability to seamlessly blend cutting-edge technology with medical expertise, enabling them to deliver accurate diagnostics and personalized healthcare solutions. This approach not only enhances patient experiences but also fortifies their position in a highly competitive marketplace.
In generating revenue, Fleury SA capitalizes on its robust infrastructure and premium service quality. The company’s business model thrives on a vast portfolio of diagnostic services, catering to an array of clientele — from individuals seeking routine checks to physicians requiring specialized analyses. Additionally, Fleury extends its reach through partnerships with hospitals and clinics, further solidifying its reputation and reliability. By maintaining a focus on operational efficiency and strategic expansions, the company ensures steady cash flows, which in turn are reinvested into technological advancements and service enhancements. This, coupled with their focus on high-quality client relations, fuels Fleury’s ability to retain a loyal customer base and sustain its financial growth trajectory.
Fleury SA, originally founded in 1926, stands as a paragon of healthcare excellence in Brazil, evolving over nearly a century into a leading provider of medical diagnostics and integrated healthcare services. Driven by a culture of innovation and customer commitment, the company operates a network of strategically located diagnostic centers, offering a comprehensive array of tests, from basic blood work to sophisticated imaging. At the core of Fleury's operations is their ability to seamlessly blend cutting-edge technology with medical expertise, enabling them to deliver accurate diagnostics and personalized healthcare solutions. This approach not only enhances patient experiences but also fortifies their position in a highly competitive marketplace.
In generating revenue, Fleury SA capitalizes on its robust infrastructure and premium service quality. The company’s business model thrives on a vast portfolio of diagnostic services, catering to an array of clientele — from individuals seeking routine checks to physicians requiring specialized analyses. Additionally, Fleury extends its reach through partnerships with hospitals and clinics, further solidifying its reputation and reliability. By maintaining a focus on operational efficiency and strategic expansions, the company ensures steady cash flows, which in turn are reinvested into technological advancements and service enhancements. This, coupled with their focus on high-quality client relations, fuels Fleury’s ability to retain a loyal customer base and sustain its financial growth trajectory.
Revenue: Q4 gross revenue was BRL 2.2 billion, up 12.2% YoY; full‑year 2025 revenue was BRL 9.0 billion, up 8.2% YoY.
Profitability: Q4 EBITDA was BRL 455.9 million (22.1% margin), up 12.5% YoY; full‑year EBITDA was BRL 2.153 billion (25.8% margin) and net income for the year was BRL 612.8 million.
Growth mix: B2C drove performance (69% of revenue) with Q4 B2C growth of 13.4% (10.2% organic); New Links grew fastest in Q4 (+24.4%), B2B grew 4.1% in Q4.
Operational efficiency: Gross profit and margins were affected in Q4 by two high‑cost drug infusions, but G&A discipline and digital initiatives are expected to drive efficiency over time.
Capital & cash: CapEx in 2025 was BRL 506.1 million (6.1% of revenue); operating cash flow for the year was BRL 2.133 billion and cash conversion was 99.9% of EBITDA.
Balance sheet: Low leverage at ~1.0x EBITDA and cash coverage sufficient for debt maturities over the next three years; ROIC improved to 16.6% (up 260 bps vs Q2 2023).
M&A and strategy: Continued disciplined M&A focused on diagnostic medicine (Confiance, Hemolab, Sao Lucas, pending Femme approval); mobile units equivalent to 72 physical PSCs are a growth lever.
Payers & commercialization: Management highlighted constructive payer dynamics (improving MLR) and closer collaboration with HMOs; denials remain elevated (~>1.4% of revenue) and are being actively managed.
